Unexpectedly, since over-expression of EGFR is commonly associated with more aggressive GBM phenotypes [69], the study found that low co-expression of HSP90 and EGFR was associated with worse prognosis for the disease, indicating an important and unconventional regulatory relationship between these two molecules, although further studies are needed to unravel the molecular mechanisms behind these results [70]. This evidence concerns the gene HSP90AA1 and glioblastoma.